CYP19A1 and breast cancer: The absolute benefit of treatment with an aromatase inhibitor versus tamoxifen in premenopausal women with HR + BC who received OFS is furthermore small, with a 10-year absolute benefit of, respectively, 2.8% for risk of recurrence and 1.9% for risk of distant recurrence [29].